Flamel Technologies SA
33 Avenue Du Drgeorges Levy
Venissieux,
69693
France - Map
Phone: 33 4 72 78 34 34
Fax: 33 4 72 78 34 35
Web Site: http://www.flamel-technologies.fr
| Flamel Technologies S.A., a biopharmaceutical company, engages in the development of polymer-based drug delivery technologies for the improvement of medical applications in France. Its Medusa nanoparticulate technology is designed to deliver therapeutic proteins, peptides, and other large and small molecules injected subcutaneously. The companys Micropump technology is a multiparticulate technology for oral administration of small molecule drugs with applications in controlled-release, taste-masking, and bioavailability enhancement. Its products based on Medusa technology include Interferon-AlphaXL, an interferon-alpha 2b for the treatment of hepatitis C virus and various oncology applications; FT-105 basal insulin, a long-acting formulation of recombinant human insulin to insulin-dependent patients; and interleukin-2 for the treatment of renal cancer. The companys products based on Micropump technology comprise Coreg CR, an extended release formulation of carvedilol phosphate for use in the treatment of moderate to severe heart failure and left ventricular dysfunction following myocardial infarction, and hypertension; and Asacard162.5mg, a controlled release formulation of aspirin, which provide therapy for cardiovascular treatment. It has strategic alliances with GlaxoSmithKline, Merck Serono, Wyeth Pharmaceuticals, Pfizer, Corning S.A., Servier, and Corning Incorporated. Flamel Technologies S.A. was founded in 1990 and is headquartered in Venissieux, France. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Stephen H. Willard , 49
Chief Exec. Officer and Member of Board of Directors |
N/A
| N/A | Mrs. Sian Crouzet ,
Principal Financial Officer and Financial Controller |
N/A
| N/A | Mr. Raphael Jorda ,
Chief Operating Officer and Exec. VP |
N/A
| N/A | Mr. Christian Kalita ,
Chief Pharmacist of Quality Assurance & Regulatory Affairs |
N/A
| N/A | Mr. Charles Mosseri-Marlio ,
Director of Strategic Planning & Investor Relations |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-06
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.31% Nasdaq 
0.05%
Profile
